Compare ACRS & CMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | CMP |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 999.1M |
| IPO Year | 2015 | 2003 |
| Metric | ACRS | CMP |
|---|---|---|
| Price | $4.51 | $21.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | $10.18 | ★ $30.75 |
| AVG Volume (30 Days) | ★ 2.4M | 302.8K |
| Earning Date | 11-05-2026 | 08-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ 0.59 |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $3.43 |
| Revenue Next Year | N/A | $2.98 |
| P/E Ratio | ★ N/A | $37.65 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.74 | $16.40 |
| 52 Week High | $6.60 | $34.50 |
| Indicator | ACRS | CMP |
|---|---|---|
| Relative Strength Index (RSI) | 40.21 | 26.15 |
| Support Level | $4.99 | $20.83 |
| Resistance Level | $5.15 | $26.18 |
| Average True Range (ATR) | 0.32 | 0.53 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 19.62 | 5.17 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.